CN112351787A - 人抗aav2衣壳多克隆抗体表位 - Google Patents

人抗aav2衣壳多克隆抗体表位 Download PDF

Info

Publication number
CN112351787A
CN112351787A CN201980041584.8A CN201980041584A CN112351787A CN 112351787 A CN112351787 A CN 112351787A CN 201980041584 A CN201980041584 A CN 201980041584A CN 112351787 A CN112351787 A CN 112351787A
Authority
CN
China
Prior art keywords
aav
gly
pro
asn
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980041584.8A
Other languages
English (en)
Chinese (zh)
Inventor
琪·阿达
萧兰·张
中井弘之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Publication of CN112351787A publication Critical patent/CN112351787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980041584.8A 2018-05-04 2019-05-06 人抗aav2衣壳多克隆抗体表位 Pending CN112351787A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862667360P 2018-05-04 2018-05-04
US62/667,360 2018-05-04
PCT/US2019/030955 WO2019213668A1 (en) 2018-05-04 2019-05-06 Human anti-aav2 capsid polyclonal antibody epitopes

Publications (1)

Publication Number Publication Date
CN112351787A true CN112351787A (zh) 2021-02-09

Family

ID=68386753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980041584.8A Pending CN112351787A (zh) 2018-05-04 2019-05-06 人抗aav2衣壳多克隆抗体表位

Country Status (5)

Country Link
US (1) US20210292370A1 (enExample)
EP (1) EP3799568A4 (enExample)
JP (2) JP2021523702A (enExample)
CN (1) CN112351787A (enExample)
WO (1) WO2019213668A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113583112A (zh) * 2021-07-30 2021-11-02 信念医药科技(苏州)有限公司 Aav特异性抗体及其应用
CN114685651A (zh) * 2022-04-15 2022-07-01 三峡大学 一种特异识别aav9衣壳蛋白的多克隆抗体及制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166208B (zh) 2018-10-02 2024-11-22 沃雅戈治疗公司 重新定向aav衣壳的嗜性
CA3161367A1 (en) * 2019-12-10 2021-06-17 Homology Medicines, Inc. Adeno-associated virus compositions and methods of use thereof
CA3177268A1 (en) 2020-05-05 2021-11-11 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
US12630842B2 (en) 2020-05-13 2026-05-19 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
CN113999861B (zh) * 2021-09-08 2024-03-15 三峡大学 腺相关病毒衣壳蛋白保守区多克隆抗体的制备方法及应用
EP4426716A1 (en) 2021-11-02 2024-09-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
JPWO2025100417A1 (enExample) * 2023-11-06 2025-05-15

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130295614A1 (en) * 2012-05-02 2013-11-07 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
US20130310443A1 (en) * 2012-05-15 2013-11-21 University Of Florida Research Foundation, Inc. Aav vectors with high transduction efficiency and uses thereof for gene therapy
CN105247044A (zh) * 2013-05-31 2016-01-13 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
US20170067908A1 (en) * 2014-04-25 2017-03-09 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2017058892A2 (en) * 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749492B2 (en) * 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
CN103502458B (zh) * 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130295614A1 (en) * 2012-05-02 2013-11-07 Sangeetha Hareendran Nucleotide sequences, methods, kit and a recombinant cell thereof
US20130310443A1 (en) * 2012-05-15 2013-11-21 University Of Florida Research Foundation, Inc. Aav vectors with high transduction efficiency and uses thereof for gene therapy
CN105247044A (zh) * 2013-05-31 2016-01-13 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
US20170067908A1 (en) * 2014-04-25 2017-03-09 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
WO2017058892A2 (en) * 2015-09-28 2017-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BRITTNEY L GURDA等: "Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8", 《J VIROL》 *
BRITTNEY L GURDA等: "Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8", 《J VIROL》, vol. 86, no. 15, 31 August 2012 (2012-08-31), pages 7739 - 7751, XP055590574, DOI: 10.1128/JVI.00218-12 *
DAMIEN MARSIC等: "Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants", 《MOL THER》 *
DAMIEN MARSIC等: "Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants", 《MOL THER》, vol. 22, no. 11, 1 November 2014 (2014-11-01), pages 1900 - 1909, XP002768344, DOI: 10.1038/mt.2014.139 *
GEORGE V ASLANIDI等: "Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?", 《PLOS ONE》 *
GEORGE V ASLANIDI等: "Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?", 《PLOS ONE》, vol. 8, no. 3, 19 March 2013 (2013-03-19), pages 59142 *
KEI ADACHI等: "Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing", 《NAT COMMUN》 *
KEI ADACHI等: "Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing", 《NAT COMMUN》, vol. 5, no. 1, 17 January 2014 (2014-01-17), pages 2 *
KEI ADACHI等: "Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing", NAT COMMUN, vol. 5, no. 1, pages 2, XP055548821, DOI: 10.1038/ncomms4075 *
NARENDRA MAHESHRI等: "Directed evolution of adeno-associated virus yields enhanced gene delivery vectors", 《NAT BIOTECHNOL》 *
NARENDRA MAHESHRI等: "Directed evolution of adeno-associated virus yields enhanced gene delivery vectors", 《NAT BIOTECHNOL》, vol. 24, no. 2, 22 January 2006 (2006-01-22), pages 198 - 204 *
P WU等: "Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism", 《J VIROL》 *
P WU等: "Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism", 《J VIROL》, vol. 74, no. 18, 15 September 2000 (2000-09-15), pages 8635 - 8647 *
谭淑萍等: "抗AAV2单克隆抗体的制备及特性研究", 《病毒学报》 *
谭淑萍等: "抗AAV2单克隆抗体的制备及特性研究", 《病毒学报》, no. 04, 15 July 2009 (2009-07-15), pages 267 - 272 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113583112A (zh) * 2021-07-30 2021-11-02 信念医药科技(苏州)有限公司 Aav特异性抗体及其应用
CN114685651A (zh) * 2022-04-15 2022-07-01 三峡大学 一种特异识别aav9衣壳蛋白的多克隆抗体及制备方法
CN114685651B (zh) * 2022-04-15 2023-07-11 三峡大学 一种特异识别aav9衣壳蛋白的多克隆抗体及制备方法

Also Published As

Publication number Publication date
EP3799568A4 (en) 2022-07-06
US20210292370A1 (en) 2021-09-23
JP2024119818A (ja) 2024-09-03
EP3799568A1 (en) 2021-04-07
WO2019213668A1 (en) 2019-11-07
JP2021523702A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
US11572637B2 (en) Methods of viral neutralizing antibody epitope mapping
US20210292370A1 (en) Human anti-aav2 capsid polyclonal antibody epitopes
US12226473B2 (en) SARS-COV-2 antigen polypeptide, recombinant adeno-associated virus expressing the polypeptide, and vaccine containing the virus
AU2022203494B2 (en) Adeno-Associated Virus Variant Capsids And Use For Inhibiting Angiogenesis
JP6921788B2 (ja) アデノ随伴ウイルスプラスミド及びベクター
JP2024020289A (ja) 祖先ウイルス配列を予測する方法およびその使用
CA2379220C (en) Structural protein of adeno-associated virus with modified antigenicity, its production and its use
JP2021175397A (ja) 祖先ウイルス配列およびその使用
CN113913464B (zh) 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用
DK3063298T3 (en) HCBI SEQUENCES AS AN EARLY MARKER FOR FUTURE DEVELOPMENT OF CANCER AND DISEASES IN CNS AND AS A TARGET FOR TREATMENT AND PREVENTION OF CANCER
JP2023540960A (ja) 操作されたａａｖベクター
JPH08504096A (ja) Ｅ型肝炎パキスタン株の組換えタンパク質ならびに診断法およびワクチンにおけるそれらの利用
CN115894672A (zh) 一种针对诺如病毒gⅱ基因型vp1蛋白的单克隆抗体及其应用
Ma et al. Sequence addition to the N-or C-terminus of the major capsid protein VP1 of norovirus affects its cleavage and assembly into virus-like particles
US20030198947A1 (en) Hepatitis virus sentinel virus I (SVI)
English et al. Rabies glycoprotein engineering for improved stability and expression
JP2001524821A (ja) Ｅ型肝炎のパキスタン株組換えタンパク質および診断法およびワクチンにおけるそれらの使用
JP2022127591A (ja) パルボウイルスの構造タンパク質およびウイルス様粒子ワクチン
US20050026257A1 (en) Production and applications for polyvalent vaccines against diseases caused by papilloma viruses
Dislers et al. Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant
CN118647391A (zh) 抗原性多肽及其用途
CN121494944A (zh) 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用
CN117660526A (zh) 一种SARS-CoV-2的免疫原及其应用
CN115418368A (zh) 一种检测SARS-CoV-2抗体中和活性的方法
HK40042402A (en) Methods of predicting ancestral virus sequences and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210209